Last reviewed · How we verify
NCT05933408
TREM-1 - a New Marker of Serious Infectious Complications in Colorectal Surgery?
trial testing TREM-1 in Colorectal (Colon or Rectal) Cancer in 64 participants. Completed in 28 February 2020.
28 February 2020
Quick facts
| Lead sponsor | Jagiellonian University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 64 |
| Start date | 1 November 2018 |
| Primary completion | 28 February 2020 |
| Estimated completion | 28 February 2020 |
| Sites | 1 location across Poland |
Drugs / interventions tested
- TREM-1
Conditions studied
- Colorectal (Colon or Rectal) Cancer — all drugs for Colorectal (Colon or Rectal) Cancer →
Sponsor
Jagiellonian University
Who can join
18 and older, any sex, with Colorectal (Colon or Rectal) Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to investigate the potential use of soluble TREM-1 (sTREM-1) to predict serious infectious complications in patients undergoing laparoscopic colorectal surgery. Patients with colon or rectal cancer, who underwent elective laparoscopic colorectal cancer surgery between November 2018 and February 2020 were included into study. Blood samples for the TREM-1 protein assay were collected from each patient four times: preoperatively and on three following postoperative days (PODs). Patients with infectious complications who formed group 1, were matched 1:1 with patients without complications (group 2). Case-matched analysis was performed by selecting patients for the control group from the group of patients paired by age, ASA scale, stage of cancer and type of surgery.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Is triggering receptor expressed on myeloid cell 1 (TREM-1) protein a new marker of serious infectious complications in colorectal surgery?: case-matched pilot study.
Pisarska-Adamczyk M, Rzepa A, Kapusta M, Zawadzka K, et al · · 2023 · cited 1× · PMID 37733081 · DOI 10.1007/s00423-023-03103-z -
Is Triggering Receptor Expressed On Myeloid Cells 1 (TREM-1) protein a new marker of serious infectious complications in colorectal surgery? – case-matched pilot study
Pisarska-Adamczyk M, Rzepa A, Kapusta M, Zawadzka K, et al · · 2023 · DOI 10.21203/rs.3.rs-3154642/v1
Verify or expand the search:
- PubMed search for NCT05933408
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Colorectal (Colon or Rectal) Cancer
Currently open trials in the same condition.
- NCT07361107 — Evaluation of Circulating Immune Response After Histosonics in Colorectal Cancer (ECHO-CRC) · Phase 1 · recruiting
- NCT06272461 — Comparison of Intravenous Lidocaine vs Ketamine in Colorectal Surgery · NA · recruiting
- NCT05051046 — Colorectal Cancer Screnning Colonoscopy Under Hypnosis · NA · recruiting
Other Jagiellonian University trials
Trials by the same sponsor.
- NCT07410767 — Advanced Endoscopic Resections for Rectal Neoplasms · not yet recruiting
- NCT07364864 — Opioid-free Anesthesia as an Alternative to General Anesthesia in Patients Undergoing Duodenopancreatic Surgery by Lapar · NA · not yet recruiting
- NCT07378189 — Opioid-free Anesthesia as an Alternative to General Anesthesia in Patients Undergoing Laparoscopic Peripheral Pancreatic · NA · not yet recruiting
- NCT07389564 — Nationwide Registry of Patients With Heart Failure With Improved and Supranormal Ejection Fraction · active not recruiting
- NCT07306689 — Posttraumatic Stress Disorder in Ectopic Pregnancy · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05933408 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jagiellonian University
- Last refreshed: 7 July 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05933408.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing